Achievement
Troutman Pepper Locke Represents Ensysce Biosciences in Acquisition of Cy Biopharma
PITTSBURGH – Troutman Pepper Locke advised Ensysce Biosciences, Inc., a clinical-stage company developing a new class of tamper-proof opioids for the …
Delivering results that matter
Across our diverse practices, we have consistently delivered remarkable outcomes for our clients. Take a closer look at how we partner with clients to help them realize their goals.
Filter By:
Applied Filters:
Achievement
Cagent Vascular Closes $41 Million Series D Financing With Guidance From Troutman Pepper Locke
PHILADELPHIA – Troutman Pepper Locke advised Cagent Vascular, Inc., a leader in endovascular technologies, in the closing of a $41 …
Achievement
Troutman Pepper Locke Supports H.C. Wainwright & Co. in Back-to-Back Outlook Therapeutics Capital Markets Transactions
CHARLOTTE – Troutman Pepper Locke recently supported H.C. Wainwright & Co., a leading investment bank, on a pair of fast-moving …
Achievement
Eupraxia Pharmaceuticals Completes $63.2 Million Public Offering With Counsel From Troutman Pepper Locke
BOSTON – Troutman Pepper Locke advised Eupraxia Pharmaceuticals, Inc. (Eupraxia) (NASDAQ: EPRX; TSX: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere technology …
Achievement
Troutman Pepper Locke Advises Eupraxia Pharmaceuticals on $80M Public Offering of Common Shares
Troutman Pepper Locke advised Eupraxia Pharmaceuticals, Inc. (Eupraxia) (NASDAQ: EPRX; TSX: EPRX), a clinical-stage biotechnology company developing targeted therapies that leverage a …
Achievement
Troutman Pepper Locke Advises Ocugen in License Agreement With Kwangdong
Troutman Pepper Locke advised Ocugen, Inc. (Ocugen), a pioneering biotechnology leader in gene therapies for blindness diseases, in the execution …
Achievement
Troutman Pepper Locke Represents MediSpend in Merger With RLDatix Subsidiary
Troutman Pepper Locke represented MediSpend, a global leading provider of compliance and stakeholder engagement solutions for the life sciences industry, …
Achievement
Troutman Pepper Represents Bloom Burton in Satellos Public Offering
Troutman Pepper advised Bloom Burton as the lead agent in a US$40M overnight marketed public offering in Canada and a …
Achievement
Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceuticals and Concurrent Private Placement
Troutman Pepper represented Palvella Therapeutics, Inc. (NASDAQ: PVLA), a clinical-stage rare disease biopharmaceutical company, in the completion of its previously …
Achievement
Troutman Pepper Represents Underwriters in Profound Medical Corp. $40.25M Public Offering
Troutman Pepper represented a syndicate of underwriters led by Raymond James Limited and Lake Street Capital Partners in Profound Medical …
Achievement
Troutman Pepper Advises Eupraxia Pharmaceuticals in Closing of a Non-Brokered Private Placement
Troutman Pepper represented Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company based in Victoria, British Columbia, in its non-brokered private placement …
Achievement
Troutman Pepper Advises Cardiol Therapeutics in Closing of Over-Allotment Option
Troutman Pepper represented Cardiol Therapeutics Inc., a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and …